Cell Transitions Contribute to Glucocorticoid-Induced Bone Loss

Area of Science:

• Bone biology
• Endothelial cell differentiation
• Glucocorticoid toxicology

Background:

• Long-term glucocorticoid therapy is a major cause of bone loss and fracture.
• The precise mechanisms underlying glucocorticoid-induced bone loss are not fully understood.

Purpose of the Study:

• To investigate the cellular and molecular mechanisms by which glucocorticoids induce bone loss.
• To explore the potential for osteoblast-lineage cells to transition into other cell types under glucocorticoid influence.

Main Methods:

• Lineage tracing studies in mice to track cell fate following glucocorticoid treatment.
• In vitro functional assays to assess bone formation and vascular repair capacities of affected cells.
• Molecular analyses to identify direct transcriptional targets of the glucocorticoid receptor.

Main Results:

• Glucocorticoids induce a reciprocal conversion of osteoblast-lineage cells into endothelial-like cells.
• Osteoblast-lineage cells treated with glucocorticoids lose bone-forming capacity but gain vascular repair function.
• The glucocorticoid receptor directly regulates Foxc2 and Osterix, key drivers of this cell transition.

Conclusions:

• Glucocorticoids promote bone loss by driving osteoblast-endothelial cell transitions.
• This previously unrecognized mechanism contributes to the skeletal toxicity of glucocorticoid therapy.
• Targeting these pathways may offer new strategies to mitigate glucocorticoid-induced bone fragility.